Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Therapeutic Drug Monitoring and Pharmacogenomics Study of Methadone Therapy (M0108)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2010 by National Health Research Institutes, Taiwan.
Recruitment status was:  Recruiting
Information provided by:
National Health Research Institutes, Taiwan Identifier:
First received: January 29, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

Addiction has been regarded as one of the most serious health and social problems in Taiwan, and heroin is currently considered to be the major substance of abuse. The most widely used treatment to date is methadone replacement therapy. It is reported that to achieve a better clinical response and to avoid possible side effects, the blood level of methadone should remain in a certain level. However, the blood level of methadone is mediated by various factors besides dosage. Genetic variability in genes that encodes enzymes affecting methadone metabolism, target receptors of methadone, and drug-drug interaction by other medication patients take will all affect blood level. Therefore, therapeutic drug monitoring (TDM) and pharmacogenomic study is crucial for evaluating and predicting the clinical response, cause of side effects or toxicity, as well as studies on drug-drug interactions.

This is a cross-sectional study in order to evaluate the relationship between methadone plasma level and clinical response in patients under methadone maintenance therapy and to identify optimal therapeutic thresholds. HPLC will be used to analyze methadone and its metabolites. Our hypothesis is that methadone plasma levels in patients who are responsive to methadone maintenance therapy are higher than level in non-responsive patients, and higher plasma level leads to less severe withdrawal symptoms. We will also test if an optimal minimal dosage exists among these patients. In the meanwhile, we will aim to test if methadone level and clinical response is correlated with different genetic polymorphism. Candidate genes that involve in pharmacokinetic and pharmacodynamic process of methadone (e.g. CYP3A4, CYP3A5, CYP2B6, ABCB1, opioid mu receptor and kappa receptor) will be genotyped for these analyses.

The results of this study will provide clinical information of methadone treatment and pharmacogenomic data in Taiwanese for clinicians to achieve a better treatment outcome.

Condition Intervention
Heroin-addicted Patients Who Undertook Methadone Maintenance Treatment
Other: no intervention applied

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional

Further study details as provided by National Health Research Institutes, Taiwan:

Estimated Enrollment: 500
Study Start Date: December 2008
Groups/Cohorts Assigned Interventions
treatment group Other: no intervention applied
no intervention applied


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
heroin-addicted patients

Inclusion Criteria:

  1. Chinese ethnicity
  2. Men or women above age of 18
  3. Able to participate in a clinical assessment in Chinese (including Mandarin and Taiwanese dialects)
  4. Diagnosis of Heroin dependence by DSM-IV definition
  5. Enter methadone maintenance therapy for at least 3 months
  6. No change of methadone dosage for the last week
  7. Regularly took methadone for the last week
  8. Individuals who have completed a written consent form

Exclusion Criteria:

  1. Patients with comorbid severe mental disorders including:

    1. Organic mental disorders, or
    2. Schizophrenia
  2. Severe cognitive impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01059747

Departments of Psychiatry, Wei-Gong Memorial Hospital
Miaoli, Taiwan
Departments of Psychiatry, China Medical University and Hospital
Taichung, Taiwan
Departments of Psychiatry, En-Chu-Kong Hospital
Taipei County, Taiwan
Departments of Psychiatry, Far-Eastern Memorial Hospital
Taipei County, Taiwan
Departments of Psychiatry, Taipei City Hospital Song-De Campus
Taipei, Taiwan
Departments of Psychiatry, Taipei City Hospital Yang-Ming Campus
Taipei, Taiwan
Departments of Psychiatry, Tao-yuan Psychiatric Center
Tao-Yuan, Taiwan
Sponsors and Collaborators
National Health Research Institutes, Taiwan
Principal Investigator: Sheng-Chang Wang, MD National Health Research Institutes, Taiwan
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Keh-Ming Lin, Director, Division of Mental Health and Addiction Medicine, National Health Research Instiutes, Taiwan Identifier: NCT01059747     History of Changes
Other Study ID Numbers: 98A1-PHPP41 
Study First Received: January 29, 2010
Last Updated: January 29, 2010
Health Authority: Taiwan: National Health Research Institutes processed this record on December 05, 2016